The latest in the onslaught of biotech initial public offerings, Spark Therapeutics (ONCE) priced at $23 on Thursday evening. Twelve hours later, the stock opened at …
In a research note issued today, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Biogen (NASDAQ:BIIB) with a $386 price target, following last …
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in today with his thoughts on Biogen Idec (NASDAQ:BIIB), following the results from a phase 2 study of …
In a research report released today, J.P.
Over the past four years, the S&P 500 has increased a total of 66%. However, the Biotech sector outperformed the S&P 500 by …
J.P.
In a research note issued today, J.P.
I have written about Biogen (NASDAQ:BIIB) previously in numerous articles as it is one of my favorite biotech names. But the positive thesis …
Cowen analyst Eric Schmidt maintained an Outperform rating on Biogen Idec (NASDAQ:BIIB) with a price target of $389, after the company reported positive interim …
Shares of Biogen Idec Inc. (NASDAQ: BIIB) increased 6.
